Source: International Congress 2015 – Differentiating COPD exacerbations from pneumonia in COPD patients
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Stefano Aliberti (Milan, Italy). Should we change our antibiotic strategy in AECOPD or CAP+COPD patients?. International Congress 2015 – Differentiating COPD exacerbations from pneumonia in COPD patients

Member's Comments

No comment yet.

Related content which might interest you: Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019 Year: 2019 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019 Year: 2019 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 May the value of FEV1 be helpful in the choice of the antibiotic therapy in acute exacerbation of COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001 COPD: antibiotic strategy in infectious exacerbations Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001 Is antibiotic treatment during asthma exacerbation necessary ? Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Does long-term macrolide treatment reduce asthma exacerbations? An individual patient data meta-analysis Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 COPD exacerbations and adherence to treatment improvement:what goal can be achieved? Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020 Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis Source: Eur Respir J, 58 (6) 2101416; 10.1183/13993003.01416-2021 Year: 2021 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Systematic review: Does antibiotic treatment duration affect the outcomes of asthma and COPD exacerbations? Source: International Congress 2017 – COPD: microbiome composition and the role of antibiotics Year: 2017 What is the role of prophylactic antibiotic therapy in chronic bronchitis or COPD? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 FEV1 is a sensible marker of healing after antibiotic treatment in severe COPD outpatients affected with AECB Source: Eur Respir J 2001; 18: Suppl. 33, 190s Year: 2001 Use of alternative therapies in patients with asthma and COPD: is there any difference? Source: Eur Respir J 2005; 26: Suppl. 49, 504s Year: 2005 How often do asthma patients claim prescribed therapy? Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS Year: 2017 Does having previous sputum results improve rationalisation of antimicrobial prescribing during acute exacerbations of COPD? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014